Suppression of esophageal cancer cell growth using curcumin, (-)-epigallocatechin-3-gallate and lovastatin

World Journal of Gastroenterology

Volumn 18, Issue 2, 2012, Pages 126-135

  Ye, Fei ^a   Zhang, Gui Hong ^a,b   Guan, Bao Xiang ^a   Xu, Xiao Chun ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

( ) epigallocatechin 3 gallate; Chemoprevention; Curcumin; Cyclooxygenase 2; Esophageal cancer; Statin

Indexed keywords

CASPASE 3; CURCUMIN; CYCLOOXYGENASE 2; EPIGALLOCATECHIN GALLATE; KI 67 ANTIGEN; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN C JUN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL INVASION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN EXPRESSION; WESTERN BLOTTING; XENOGRAFT;

EID: 84862915449     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v18.i2.126     Document Type: Article

References (44)

1. Stoner GD, Gupta A. Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis 2001; 22: 1737-1746
2. Chen X, Yang CS. Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis 2001; 22: 1119-1129.
3. Xu XC. Risk factors and gene expression in esophageal cancer. Methods Mol Biol 2009; 471: 335-360.
4. Xu XC. Tumor-suppressive activity of retinoic acid receptorbeta in cancer. Cancer Lett 2007; 253: 14-24
5. Liang ZD, Lippman SM, Wu TT, Lotan R, Xu XC. RRIG1 mediates effects of retinoic acid receptor beta2 on tumor cell growth and gene expression through binding to and inhibition of RhoA. Cancer Res 2006; 66: 7111-7118
6. Huang J, Liang ZD, Wu TT, Hoque A, Chen H, Jiang Y, Zhang H, Xu XC. Tumor-suppressive effect of retinoid receptor- induced gene-1 (RRIG1) in esophageal cancer. Cancer Res 2007; 67: 1589-1593
7. Sporn MB, Newton DL. Chemoprevention of cancer with retinoids. Fed Proc 1979; 38: 2528-2534.
8. Wolbach SB. Effects of vitamin A deficiency and hypervitaminosis in animals. In: Sebrell WH, Harris RS. The Vitamins. New York: Academic Press, 1956: 106-137
9. Inayama Y, Kitamura H, Shibagaki T, Usuda Y, Ito T, Nakatani Y, Kanisawa M. In vivo growth and differentiation potential of tracheal basal cells of rabbits in vitamin A deficiency. Int J Exp Pathol 1996; 77: 89-97
10. Han J. Highlights of the cancer chemoprevention studies in China. Prev Med 1993; 22: 712-722
11. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, Yang CS, Zheng SF, Gail M, Li GY. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/ mineral combinations, cancer incidence, and diseasespecific mortality in the general population. J Natl Cancer Inst 1993; 85: 1483-1492
12. Li JY, Taylor PR, Li B, Dawsey S, Wang GQ, Ershow AG, Guo W, Liu SF, Yang CS, Shen Q. Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J Natl Cancer Inst 1993; 85: 1492-1498
13. Xu XC, Liu X, Tahara E, Lippman SM, Lotan R. Expression and up-regulation of retinoic acid receptor-beta is associated with retinoid sensitivity and colony formation in esophageal cancer cell lines. Cancer Res 1999; 59: 2477-2483
14. Gupta A, Nines R, Rodrigo KA, Aziz RA, Carlton PS, Gray DL, Steele VE, Morse MA, Stoner GD. Effects of dietary N-(4-hydroxyphenyl)retinamide on N-nitrosomethylbenzylamine metabolism and esophageal tumorigenesis in the Fischer 344 rat. J Natl Cancer Inst 2001; 93: 990-998
15. Daniel EM, Stoner GD. The effects of ellagic acid and 13-cisretinoic acid on N-nitrosobenzylmethylamine-induced esophageal tumorigenesis in rats. Cancer Lett 1991; 56: 117-124
16. Xu XC. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs 2002; 13: 127-137
17. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, Schoenberg JB, West AB, Rotterdam H, Fraumeni JF, Blot WJ. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998; 7: 97-102
18. Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995; 76: 1116-1119.
19. Gupta RA, DuBois RN. Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett' s esophagus. J Natl Cancer Inst 2002; 94: 406-407
20. Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA, Krishnadath KK, Lutzke LS, Burgart LJ. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002; 122: 1101-1112
21. Buttar NS, Wang KK, Anderson MA, Dierkhising RA, Pacifico RJ, Krishnadath KK, Lutzke LS. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J Natl Cancer Inst 2002; 94: 422-429
22. Li M, Lotan R, Levin B, Tahara E, Lippman SM, Xu XC. Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention. Cancer Epidemiol Biomarkers Prev 2000; 9: 545-549
23. Li M, Wu X, Xu XC. Induction of apoptosis by cyclo-oxygenase- 2 inhibitor NS398 through a cytochrome C-dependent pathway in esophageal cancer cells. Int J Cancer 2001; 93: 218-223
24. Shureiqi I, Xu X, Chen D, Lotan R, Morris JS, Fischer SM, Lippman SM. Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase- 1 expression. Cancer Res 2001; 61: 4879-4884
25. Xu XC, Shappell SB, Liang Z, Song S, Menter D, Subbarayan V, Iyengar S, Tang DG, Lippman SM. Reduced 15Slipoxygenase- 2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. Neoplasia 2003; 5: 121-127
26. Waxman HA. The lessons of Vioxx--drug safety and sales. N Engl J Med 2005; 352: 2576-2578.
27. Andersohn F, Suissa S, Garbe E. Risks and benefits of celecoxib to prevent colorectal adenomas. N Engl J Med 2006; 355: 2371; author reply 2371-2373
28. Huang MT, Lou YR, Ma W, Newmark HL, Reuhl KR, Conney AH. Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res 1994; 54: 5841-5847
29. Li ZG, Shimada Y, Sato F, Maeda M, Itami A, Kaganoi J, Komoto I, Kawabe A, Imamura M. Inhibitory effects of epigallocatechin-3-gallate on N-nitrosomethylbenzylamineinduced esophageal tumorigenesis in F344 rats. Int J Oncol 2002; 21: 1275-1283
30. Hoque A, Lippman SM, Wu TT, Xu Y, Liang ZD, Swisher S, Zhang H, Cao L, Ajani JA, Xu XC. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis 2005; 26: 785-791
31. Aggarwal S, Takada Y, Singh S, Myers JN, Aggarwal BB. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer 2004; 111: 679-692
32. Shishodia S, Potdar P, Gairola CG, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates cigarette smokeinduced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis 2003; 24: 1269-1279
33. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W, Yang CS. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylationsilenced genes in cancer cell lines. Cancer Res 2003; 63: 7563-7570
34. Wang ZY, Wang LD, Lee MJ, Ho CT, Huang MT, Conney AH, Yang CS. Inhibition of N-nitrosomethylbenzylamineinduced esophageal tumorigenesis in rats by green and black tea. Carcinogenesis 1995; 16: 2143-2148
35. Rafiee P, Nelson VM, Manley S, Wellner M, Floer M, Binion DG, Shaker R. Effect of curcumin on acidic pH-induced expression of IL-6 and IL-8 in human esophageal epithelial cells (HET-1A): role of PKC, MAPKs, and NF-kappaB. Am J Physiol Gastrointest Liver Physiol 2009; 296: G388-G398
36. O'Sullivan-Coyne G, O'Sullivan GC, O'Donovan TR, Piwocka K, McKenna SL. Curcumin induces apoptosis-independent death in oesophageal cancer cells. Br J Cancer 2009; 101: 1585-1595
37. Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 2008; 103: 825-837
38. Conney AH. Enzyme induction and dietary chemicals as approaches to cancer chemoprevention: the Seventh DeWitt S. Goodman Lecture. Cancer Res 2003; 63: 7005-7031
39. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003; 23: 363-398
40. Ushida J, Sugie S, Kawabata K, Pham QV, Tanaka T, Fujii K, Takeuchi H, Ito Y, Mori H. Chemopreventive effect of curcumin on N-nitrosomethylbenzylamine-induced esophageal carcinogenesis in rats. Jpn J Cancer Res 2000; 91: 893-898
41. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005; 5: c930-942
42. Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004; 30: 609-641
43. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002; 105: 739-745
44. Vincent L, Chen W, Hong L, Mirshahi F, Mishal Z, Mirshahi- Khorassani T, Vannier JP, Soria J, Soria C. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett 2001; 495: 159-166